Abstract P4-11-13: Prevalence of treatment-related symptoms in patients with breast cancer undergoing (neo)adjuvant endocrine therapy with or without chemotherapy for early stage breast cancer
Authors: Mortimer Joanne , Moore Sharla , Patel Niki , Sedrak Mina , Stewart Daphne , Yuan Yuan , Waisman James , Bradford Brittany , Loscalzo Matthew , Clark Karen , Razavi Marianne 
Published: March 2022

Abstract
Prevalence of treatment-related symptoms in patients with breast cancer undergoing (neo)adjuvant endocrine therapy with or without chemotherapy for early stage breast cancer. Background: Survivorship care plans require identification of post-treatment problems.Methods: After completion of (neo) adjuvant therapy and immediately prior to a survivorship visit which included a treatment summary and care planning, patients completed an automated tablet-based series of 25 biopsychosocial questions (Survivorship-SupportScreen). Problems were identified and rated on a Likert scale of 1-5. This analysis addresses the differences in patient reported symptoms in women treated with endocrine therapy (ET) alone compared to those receiving chemotherapy and ET (CT+ET). Results: 204 women with a mean age of 57.5 years at screening time (Range 27-90) completed the Survivorship-SupportScreen within a median of 0.9 years of initial diagnosis. The 113 patients receiving CT+ET were younger than the 91 treated with ET alone (Mean 54.83 versus 60.89, with p&lt;0.001) with no significant difference in time from first diagnosis to screening.
Prevalence of problems was similar for both groups, except for neuropathy (p&lt;0.001). By Logistic regression models neuropathy was 2.5 times more likely in patients treated with chemotherapy. Patients ≥ 50 years treated with CT+ET reported more hot flashes and lack of regular exercise: OR=2.18, p=0.024, and OR=2.04, p=0.033. Conclusions: We have demonstrated the feasibility of screening patient as they transition from active treatment to survivorship. Except for neuropathy, all patients receiving CT+ET had similar problems compared with those on ET alone. Women ≥ 50 years who received CT+ET, were more likely to report hot flashes and lack of regular exercise. Despite the fact that most of these women are likely cured of their cancer, the negative lingering sequelae of problem-related distress were reported by all patients.
CT+ETET alonepFatigue81/110 (73.64%)65/88 (73.86%)0.971Worry about recurrence77/113 (68.14%)60/91 (65.93%)0.739Sleeping70/112 (62.5%)51/91 (56.04%)0.351Not being physically active67/110 (60.9%)50/89 (56.18%)0.500Neuropathy64/113 (56.64%)29/91 (31.87%)&lt;0.001Pain62/112 (55.36%)43/90 (47.78%)0.284Hot flashes61/113 (53.98%)52/91 (57.14%)0.652Thinking clearly53/111 (47.75%)38/89 (42.7%)0.476Vaginal dryness47/113 (41.59%)31/91 (34.07%)0.271Gained weight45/113 (39.82%)34/91 (37.36%)0.720
Citation Format: Joanne Mortimer, Sharla Moore, Niki Patel, Mina Sedrak, Daphne Stewart, Yuan Yuan, James Waisman, Brittany Bradford, Matthew Loscalzo, Karen Clark, Marianne Razavi. Prevalence of treatment-related symptoms in patients with breast cancer undergoing (neo)adjuvant endocrine therapy with or without chemotherapy for early stage breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-11-13.